<code id='830AFDB62B'></code><style id='830AFDB62B'></style>
    • <acronym id='830AFDB62B'></acronym>
      <center id='830AFDB62B'><center id='830AFDB62B'><tfoot id='830AFDB62B'></tfoot></center><abbr id='830AFDB62B'><dir id='830AFDB62B'><tfoot id='830AFDB62B'></tfoot><noframes id='830AFDB62B'>

    • <optgroup id='830AFDB62B'><strike id='830AFDB62B'><sup id='830AFDB62B'></sup></strike><code id='830AFDB62B'></code></optgroup>
        1. <b id='830AFDB62B'><label id='830AFDB62B'><select id='830AFDB62B'><dt id='830AFDB62B'><span id='830AFDB62B'></span></dt></select></label></b><u id='830AFDB62B'></u>
          <i id='830AFDB62B'><strike id='830AFDB62B'><tt id='830AFDB62B'><pre id='830AFDB62B'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:624
          Cambridge: AbbVie
          The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

          WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

          AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

          advertisement

          The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          FDA has safety concerns on CRISPR
          FDA has safety concerns on CRISPR

          AdobeTheFoodandDrugAdministrationsaidonFridaythatithassomesafetyconcernsaboutanexperimentalCRISPR-ba

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Readout Newsletter: XBI biotech index, Akero Therapeutics

          Wanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyourinb